Prompt identification of Alzheimer's disease with brain PET imaging of a woman with multiple previous diagnoses of other neuropsychiatric conditions.

D. Silverman,G. Small

DOI: https://doi.org/10.1176/APPI.AJP.159.9.1482

IF: 17.7

2002-09-01

American Journal of Psychiatry

Abstract:Clinical identification and differential diagnosis of dementia is especially challenging in its early stages, partly because of the difficulty in distinguishing it from the mild decline in memory that can occur with normal aging and from mild cognitive manifestations of other neuropsychiatric conditions, such as depression. As reported by the U.S. Agency for Health Care Policy and Research in 1996 (1), “Early recognition of the condition has important benefits,” which is even more the case today, now that several medications for the treatment of Alzheimer’s disease are available by prescription; however, “early-stage dementia is often unrecognized or misdiagnosed.” This is especially unfortunate for dementias like Alzheimer’s due to neurodegenerative disease, since patients potentially have the most to gain from effective therapies that intervene as early as possible in the course of progressive irreversible damage to brain tissue. The University of California, Los Angeles, Memory Clinic is primarily directed toward serving patients with mild memory changes who frequently have not experienced sufficient cognitive losses to meet diagnostic criteria for dementia. The mission of the clinic is driven by clinicopathological studies of recent years indicating that a substantial portion of such individuals are actually suffering from the earliest manifestations of Alzheimer’s disease and related dementias, while conventional methods for evaluating those patients are inadequate for making reliable diagnostic and prognostic assessments. During the same period, advances in dementia research have identified genetic and environmental factors that significantly increase the risk of developing neurodegenerative disease; moreover, it has become increasingly evident that measurement of regional cerebral metabolism through positron emission tomography (PET) sensitively detects such disease at the time of its earliest symptomatic expression, or even preclinically. Although new PET technologies (2) are being developed to measure the concentration of amyloid plaques and neurofibrillary tangles, the pathognomonic lesions of Alzheimer’s disease, this technology is as yet available in clinical settings. By contrast, PET measurements of cerebral glucose metabolism are clinically available; considerable evidence indicates their usefulness in the early diagnosis of dementia. The clinical case described illustrates the typical outcomes of a conventional evaluation process and the dementia evaluation process as it is carried out in our memory clinic.